MetLife, Inc. (NYSE:MET) slipped over -0.55% at $52.85. MetLife, Inc. has 1.06 billion shares outstanding, and in the last trade has seen ATR around 0.7. The volume of MET witnessed a shift from 3.11 million shares, based on a 50-day average, to 5.51 million shares.
In the most updated research from a number of analysts on Wall Street, the company gets 10 Buys and 1 Sell among 15 analysts. MetLife, Inc. (NYSE:MET)has consensus analyst target price is $54.82. That gives us a street projected return of 3.73%. If the published price targets set by MetLife, Inc. analysts have any power to influence the stock’s share price, the highest price target set for MET is $60.
MetLife, Inc. most recently reported earnings per share (EPS) of $1.3 for the June 2017 versus $0.83 in the same quarter last year, representing 57% growth. Analysts had predicted $1.28. Revenue during the quarter was $17.39 billion, representing 3% growth from $16.96 billion in year-ago quarter. The company’s quarterly EPS surprised Wall Street by as much as 2% to the upside in its last earnings announcement, so investors should note this tendency when assessing consensus estimates.
On a similar note, analysts expect EPS of $0.97 in September 2017 quarter and $1.1 in December 2017 quarter, representing -24.22% and -18.52% growth, respectively. They expect this year’s earnings to fall -6.1% year-over-year to $4.31, followed by 10.44% growth in the next year to $4.76.
Shares of Hologic, Inc. (NASDAQ:HOLX) traded down -0.54% in the last session while performance was up 36.66% in the last five days. The stock’s last price was lower from the average trading price of 50 days recorded at $38 while enlarging the period to 200 trading days, the average price was $41.55. Currently, 280.4 million total shares are owned by the public and among those 279.69 million shares have been available to trade. The percentage of shares being held by the company management was 0.1% while institutional stake was 0%.
Hologic, Inc. (HOLX) is recuperating from the fall at $35.15, the 52-week low. The stock has risen 4.3% since then. The trading saw a strength at $46.8 , the 52-week high. But since then, those gains have faded by -21.67%. HOLX has lost -4.01% in the 1-month period.
MetLife, Inc. has a beta of 0.94, offering the possibility of a higher rate of return, but also posing more risk. The portion of a company’s profit allocated to each outstanding share of common stock was $2.68 a share in the trailing twelve months. It last reported revenues of $806.1 million and EPS of $0.5 for the June 2017, representing 12% top-line growth and 0.51 EPS growth.
Looking forward, the company’s quarterly earnings are expected to come at $0.49 in the three months through September 2017 and $0.52 in the quarter ending December 2017, reflecting -5.77% and 0% growth, respectively. For the full year, analysts expect earnings to jump 2.55% yoy to $2.01. Next year this growth will reach 7.46% to attain $2.16.